Surgalign Holdings and Aziyo Biologics Announce Expanded Distribution Agreement
November 16 2020 - 4:05PM
Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine
company focused on advancing spine surgery including through the
application of digital technologies to improve patient outcomes,
and Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage
regenerative medicine company, today announced an updated
distribution agreement and expanded product offering whereby Aziyo
will provide ViBone® Moldable to Surgalign for distribution in the
U.S. ViBone Moldable joins Surgalign’s orthobiologic solutions to
support spinal fusion, which currently include ViBone and other
advanced bone graft solutions.
More about
ViBone Moldable
Similar to ViBone, ViBone Moldable is a
next-generation viable cell bone matrix processed using a
proprietary method optimized to protect and preserve the health of
native bone cells to potentially enhance new bone formation. It
contains cancellous bone particles as well as demineralized
cortical bone particles and fibers, delivering the necessary
components for bone formation (osteoinduction, osteoconduction and
osteogenesis) along with excellent handling and cohesive
properties.
“We are excited about the addition of ViBone
Moldable to Surgalign’s bone grafting solutions to enhance our
surgeon customer experience. ViBone Moldable combines Aziyo’s
expertise in viable cellular allograft bone matrix processing with
handling enhancements for a better operating room experience,” said
Terry Rich, President and Chief Executive Officer of Surgalign
Holdings. “With this addition, Surgalign continues to focus on
delivering innovative solutions for improved patient outcomes.”
“We are delighted to have the opportunity to
expand our existing relationship with Surgalign, and to deliver the
benefits of ViBone Moldable through their commercial organization,”
said Ron Lloyd, President and CEO of Aziyo. “The orthopedic and
spinal repair market is estimated to be a $2 billion market
opportunity, with 1.5 million annual orthopedic and spinal repair
procedures using biologic materials. We are confident that ViBone
Moldable will be a great addition to the Surgalign portfolio of
viable bone matrices addressing this significant market need.”
About Surgalign Holdings, Inc.
Surgalign Holdings, Inc. is a global medical
technology company advancing the science of spine care, focused on
delivering innovative solutions that drive superior clinical and
economic outcomes. The company is building off a legacy of high
quality and differentiated products, and continues to invest in
clinically validated innovation to deliver better surgical outcomes
and improve patient’s lives. Surgalign markets products throughout
the United States and in more than 50 countries worldwide through
an expanding network of top independent distributors. Surgalign, a
member of AdvaMed, is headquartered in Deerfield, IL, with
commercial, innovation and design centers in San Diego, CA,
Marquette, MI, and Wurmlingen, Germany. Learn more at
www.surgalign.com and connect on LinkedIn and Twitter.
About Aziyo Biologics
Aziyo Biologics is a commercial-stage
regenerative medicine company focused on creating the next
generation of differentiated products and improving outcomes in
patients undergoing surgery, concentrating on patients receiving
implantable medical devices. Since its founding in 2015, Aziyo
Biologics has created a portfolio of commercial-stage products used
in cardiovascular, orthopedic, and reconstructive specialties. For
more information, visit www.Aziyo.com.
Forward Looking Statement
This communication contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements regarding the addressable
market and Surgalign’s and Aziyo’s ability to satisfy this need.
These forward-looking statements are based on Surgalign’s and
Aziyo’s management’s current expectations, estimates and
projections about their industry, their respective management's
beliefs and certain assumptions made by such management. Words such
as "anticipates," "expects," "intends," "plans," "believes,"
"seeks," "estimates," “will” and variations of such words and
similar expressions are intended to identify such forward-looking
statements. These statements are not guarantees of future
performance and are subject to risks and uncertainties, including
the risks described in Surgalign’s and Aziyo’s public filings with
the U.S. Securities and Exchange Commission including, but not
limited to, those described under the section entitled “Risk
Factors” of such filings. Any such forward-looking statements speak
as of the date of this press release. Actual results may differ
materially from the anticipated results reflected in these
forward-looking statements. Except as required by applicable law,
neither Surgalign nor Aziyo undertake any obligation to publicly
update or revise any forward-looking statements contained herein,
whether as a result of any new information, future events, changed
circumstances or otherwise.
Surgalign Investor Contact: |
|
Aziyo
Investor Contact: |
|
Aziyo
Media Contact: |
Jonathon Singer |
|
Leigh Salvo or Caroline Paul |
|
Courtney Guyer |
Investor and Media Contact |
|
Gilmartin Group |
|
Aziyo Biologics, Inc. |
jsinger@surgalign.com |
|
investors@aziyo.com |
|
PR@aziyo.com |
+1 224 303 4651 |
|
|
|
|
Surgalign (NASDAQ:SRGA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Surgalign (NASDAQ:SRGA)
Historical Stock Chart
From Apr 2023 to Apr 2024